La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Imunon Gestione

Gestione criteri di controllo 3/4

Imunon's Il CEO è Stacy Lindborg, nominato in May2024, ha un mandato di meno di un anno. possiede direttamente 1.83% delle azioni della società, per un valore di $ 327.57K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.4 anni e 5.9 anni.

Informazioni chiave

Stacy Lindborg

Amministratore delegato

US$44.1k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	1.8%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Stacy Lindborg (53 yo)

less than a year

Mandato

US$44,095

Compensazione

Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Tardugno	Executive Chairman	17.7yrs	Nessun dato	2.45% $ 367.5k
Stacy Lindborg	President	less than a year	US$44.10k	1.83% $ 274.7k
Khursheed Anwer	Executive VP & Chief Scientific Officer	10.3yrs	US$680.16k	0.020% $ 3.0k
David Gaiero	CFO & Corporate Secretary	less than a year	Nessun dato	Nessun dato
Timothy Tumminello	Chief Accounting Officer & Controller	14.7yrs	US$137.75k	Nessun dato
Sebastien Hazard	Executive VP & Chief Medical Officer	less than a year	Nessun dato	0.14% $ 20.8k

1.5yrs

Durata media

58.5yo

Età media

Gestione esperta: Il team dirigenziale di 0HUZ non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Tardugno	Executive Chairman	17.7yrs	Nessun dato	2.45% $ 367.5k
Stacy Lindborg	President	3.3yrs	US$44.10k	1.83% $ 274.7k
Christine Pellizzari	Independent Director	3.3yrs	US$47.70k	0% $ 0
Donald Braun	Independent Director	8.8yrs	US$72.90k	0.0042% $ 621.5
Wafik El-Deiry	Member of Advisory Board	no data	Nessun dato	Nessun dato
David Cheresh	Member of Advisory Board	no data	Nessun dato	Nessun dato
Michael Weinblatt	Member of Advisory Board	no data	Nessun dato	Nessun dato
James Dentzer	Independent Director	2yrs	US$61.20k	0% $ 0
Frederick Fritz	Independent Director	13.2yrs	US$106.20k	0.082% $ 12.2k
Jerry Glickson	Member of Advisory Board	no data	Nessun dato	Nessun dato
Mark Dewhirst	Member of Advisory Board	no data	Nessun dato	Nessun dato
Peter Corry	Member of Advisory Board	no data	Nessun dato	Nessun dato

6.0yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0HUZ sono considerati esperti (durata media dell'incarico 5.9 anni).

Imunon Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

Recent updates

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Financial position

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.59 loss per share (vs US$2.19 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media